Last reviewed · How we verify
STA-5312
At a glance
| Generic name | STA-5312 |
|---|---|
| Sponsor | Synta Pharmaceuticals Corp. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors (PHASE1)
- STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STA-5312 CI brief — competitive landscape report
- STA-5312 updates RSS · CI watch RSS
- Synta Pharmaceuticals Corp. portfolio CI